NASDAQ:ZGNX - Zogenix Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $60.95 -0.40 (-0.65 %) (As of 07/17/2018 03:59 AM ET)Previous Close$61.35Today's Range$59.70 - $62.4052-Week Range$10.05 - $62.75Volume961,200 shsAverage Volume623,550 shsMarket Capitalization$2.16 billionP/E Ratio-15.09Dividend YieldN/ABeta1.83 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California. Receive ZGNX News and Ratings via Email Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNASDAQ:ZGNX CUSIP98978L10 Webwww.zogenix.com Phone510-550-8300 Debt Debt-to-Equity RatioN/A Current Ratio12.19 Quick Ratio12.19 Price-To-Earnings Trailing P/E Ratio-15.09 Forward P/E Ratio-15.67 P/E GrowthN/A Sales & Book Value Annual Sales$9.82 million Price / Sales218.60 Cash FlowN/A Price / CashN/A Book Value$8.80 per share Price / Book6.93 Profitability EPS (Most Recent Fiscal Year)($4.02) Net Income$-126,810,000.00 Net MarginsN/A Return on Equity-66.94% Return on Assets-40.43% Miscellaneous Employees68 Outstanding Shares35,220,000Market Cap$2,160.93 Zogenix (NASDAQ:ZGNX) Frequently Asked Questions What is Zogenix's stock symbol? Zogenix trades on the NASDAQ under the ticker symbol "ZGNX." How were Zogenix's earnings last quarter? Zogenix, Inc. (NASDAQ:ZGNX) posted its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.13. During the same period in the prior year, the business earned ($0.86) EPS. View Zogenix's Earnings History. What price target have analysts set for ZGNX? 5 Wall Street analysts have issued twelve-month price targets for Zogenix's stock. Their forecasts range from $54.00 to $69.00. On average, they expect Zogenix's stock price to reach $61.00 in the next year. This suggests a possible upside of 0.1% from the stock's current price. View Analyst Ratings for Zogenix. What is the consensus analysts' recommendation for Zogenix? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Zogenix stock? Here are some recent quotes from research analysts about Zogenix stock: 1. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel DosePro is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (6/21/2018) 2. Mizuho analysts commented, "We are confident ahead of this data and we expect the readout to be an important share moving event and the last major hurdle prior to submission of the NDA." (5/10/2018) Who are some of Zogenix's key competitors? Some companies that are related to Zogenix include Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Loxo Oncology (LOXO), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO) and Madrigal Pharmaceuticals (MDGL). Who are Zogenix's key executives? Zogenix's management team includes the folowing people: Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 59)Mr. Roger L. Hawley B.S., Co-Founder & Director (Age 65)Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 50)Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 56)Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 54) Has Zogenix been receiving favorable news coverage? News articles about ZGNX stock have been trending somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zogenix earned a coverage optimism score of 0.02 on Accern's scale. They also gave media stories about the company an impact score of 45.15 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. Who are Zogenix's major shareholders? Zogenix's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Xact Kapitalforvaltning AB (0.02%). Company insiders that own Zogenix stock include Bradley S Galer, Cam L Garner, Gail M Farfel, Life Sciences Maste Perceptive, Renee P Tannenbaum and Roger Hawley. View Institutional Ownership Trends for Zogenix. Which institutional investors are buying Zogenix stock? ZGNX stock was acquired by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB. Company insiders that have bought Zogenix stock in the last two years include Bradley S Galer, Life Sciences Maste Perceptive and Renee P Tannenbaum. View Insider Buying and Selling for Zogenix. How do I buy shares of Zogenix? Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Zogenix's stock price today? One share of ZGNX stock can currently be purchased for approximately $60.95. How big of a company is Zogenix? Zogenix has a market capitalization of $2.16 billion and generates $9.82 million in revenue each year. The company earns $-126,810,000.00 in net income (profit) each year or ($4.02) on an earnings per share basis. Zogenix employs 68 workers across the globe. How can I contact Zogenix? Zogenix's mailing address is 5858 Horton Street Suite 455, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected] MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 292 (Vote Outperform)Underperform Votes: 186 (Vote Underperform)Total Votes: 478MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: What do investors mean by earnings per share?